Prasad Harish C, Steiner Jennifer A, Sutcliffe James S, Blakely Randy D
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-8548, USA.
Philos Trans R Soc Lond B Biol Sci. 2009 Jan 27;364(1514):163-73. doi: 10.1098/rstb.2008.0143.
Rare, functional, non-synonymous variants in the human serotonin (5-hydroxytryptamine, 5-HT) transporter (hSERT) gene (SLC6A4) have been identified in both autism and obsessive-compulsive disorder (OCD). Within autism, rare hSERT coding variants associate with rigid-compulsive traits, suggesting both phenotypic overlap with OCD and a shared relationship with disrupted 5-HT signalling. Here, we document functional perturbations of three of these variants: Ile425Leu; Phe465Leu; and Leu550Val. In transiently transfected HeLa cells, the three variants confer a gain of 5-HT transport phenotype. Specifically, enhanced SERT activity was also observed in lymphoblastoid lines derived from mutation carriers. In contrast to previously characterized Gly56Ala, where increased transport activity derives from catalytic activation, the three novel variants exhibit elevated surface density as revealed through both surface antagonist-binding and biotinylation studies. Unlike Gly56Ala, mutants Ile425Leu, Phe465Leu and Leu550Val retain a capacity for acute PKG and p38 MAPK regulation. However, both Gly56Ala and Ile425Leu demonstrate markedly reduced sensitivity to PP2A antagonists, suggesting that deficits in trafficking and catalytic modulation may derive from a common basis in perturbed phosphatase regulation. When expressed stably from the same genomic locus in CHO cells, both Gly56Ala and Ile425Leu display catalytic activation, accompanied by a striking loss of SERT protein.
在自闭症和强迫症(OCD)中均已发现人类血清素(5-羟色胺,5-HT)转运体(hSERT)基因(SLC6A4)中存在罕见的功能性非同义变体。在自闭症患者中,罕见的hSERT编码变体与刻板强迫特征相关,这表明其与OCD存在表型重叠,且与5-HT信号传导紊乱存在共同关联。在此,我们记录了其中三个变体的功能扰动:Ile425Leu、Phe465Leu和Leu550Val。在瞬时转染的HeLa细胞中,这三个变体呈现出5-HT转运表型增强。具体而言,在源自突变携带者的淋巴母细胞系中也观察到了增强的SERT活性。与先前表征的Gly56Ala不同,Gly56Ala的转运活性增加源自催化激活,而通过表面拮抗剂结合和生物素化研究表明,这三个新变体呈现出升高的表面密度。与Gly56Ala不同,Ile425Leu、Phe465Leu和Leu550Val突变体保留了对急性PKG和p38 MAPK调节的能力。然而,Gly56Ala和Ile425Leu对PP2A拮抗剂的敏感性均显著降低,这表明转运和催化调节缺陷可能源自磷酸酶调节紊乱的共同基础。当在CHO细胞中从相同基因组位点稳定表达时,Gly56Ala和Ile425Leu均表现出催化激活,并伴有SERT蛋白的显著丧失。